# Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy

> **NCT03982277** · PHASE2 · COMPLETED · sponsor: **Makerere University** · enrollment: 130 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Rifampin 300 Mg Oral Capsule

## Key facts

- **NCT ID:** NCT03982277
- **Lead sponsor:** Makerere University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-30
- **Primary completion:** 2021-03-16
- **Final completion:** 2021-07-23
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2023-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03982277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03982277, "Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03982277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*